Can clinical tests help monitor human papillomavirus vaccine impact?

Meites, Elissa; Lin, Carol; Unger, Elizabeth R.; Steinau, Martin; Patel, Sonya; Markowitz, Lauri E.; Hariri, Susan

doi:10.1002/ijc.28115

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Can clinical tests help monitor human papillomavirus vaccine impact?

9 1 2013
By Meites, Elissa ; Lin, Carol ; Unger, Elizabeth R. ; ...
http://dx.doi.org/10.1002/ijc.28115
Source: Int J Cancer. 133(5):1101-1106

[PDF-275.52 KB]

English

Details Supporting Files You May Also Like

Details:

Alternative Title:

Int J Cancer
Personal Author:

Meites, Elissa ; Lin, Carol ; Unger, Elizabeth R. ; Steinau, Martin ; Patel, Sonya ; ... More +

Meites, Elissa ; Lin, Carol ; Unger, Elizabeth R. ; Steinau, Martin ; Patel, Sonya ; Markowitz, Lauri E. ; Hariri, Susan Less -
Description:

As immunization programs for human papillomavirus (HPV) are implemented more widely around the world, interest is increasing in measuring their impact. One early measurable impact of HPV vaccine is on the prevalence of specific HPV types in a population. In low-resource settings, a potentially attractive strategy would be to monitor HPV prevalence using clinical cervical cancer screening test results to triage specimens for HPV typing. We assessed this approach in a nationally representative population of U.S. females aged 14-59 years. Using self-collected cervico-vaginal swab specimens from 4,150 women participating in the National Health and Nutrition Examination Survey during 2003-2006, we evaluated type-specific HPV prevalence detected by the Roche linear array (LA) research test on all specimens, compared with type-specific HPV prevalence detected by LA conducted only on specimens positive by the digene hybrid capture 2 (HC-2) clinical test. We calculated weighted prevalence estimates and their 95% confidence intervals (CIs), and examined relative type-specific HPV prevalence according to the two testing approaches. The population prevalence of oncogenic HPV vaccine types 16/18 was 6.2% (CI:5.4-7.1) by LA if all specimens were tested, and 2.4% (CI:1.9-3.0) if restricted to positive HC-2. Relative prevalence of individual HPV types was similar for both approaches. Compared with typing all specimens, a triage approach would require testing fewer specimens, but a greater reduction in HPV prevalence or a larger group of specimens would be needed to detect vaccine impact. Further investigation is warranted to inform type-specific HPV monitoring approaches around the world.
Subjects:

[+]

Adolescent Adult Female Humans Middle Aged Papillomaviridae Papillomavirus Infections Papillomavirus Vaccines Prevalence
Keywords:

[+]

DNA Probes Epidemiology HPV Laboratories Papillomavirus Infections Papillomavirus Vaccines Population Surveillance
Source:

Int J Cancer. 133(5):1101-1106
Pubmed ID:

23420411
Pubmed Central ID:

PMC4692361
Document Type:

Journal Article
Funding:

CC999999/ImCDC/Intramural CDC HHSUnited States/
Volume:

133
Issue:

5
Collection(s):

CDC Public Access
Main Document Checksum:

[+]

urn:sha256:01cf47a8a38dd23c7cf4bd97f5a5eea2f28a424f9b7586473a4eaf4196d98781
Download URL:

https://stacks.cdc.gov/view/cdc/37105/cdc_37105_DS1.pdf
File Type:

	nihms-743264-f0001.gif	gif
	nihms-743264-f0001.jpg	jpeg
	nihms-743264.nxml	xml

More +